Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Colonic Neoplasms 1Adenocarcinoma of the Prostate 1

Interventions

enzalutamide 2pazopanib 1capivasertib 1STA 9090 1Dutasteride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of the Prostate × STA 9090 × Clear all
NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡